STRATA Skin Sciences Inc Cash Flow Conversion Efficiency
STRATA Skin Sciences Inc cash flow conversion efficiency. Based on the latest financial reports, STRATA Skin Sciences Inc (SSKN) has a cash flow conversion efficiency ratio of -0.082x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-239.00K) by net assets ($2.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of STRATA Skin Sciences Inc (2003–2025)
Cash flow conversion efficiency of STRATA Skin Sciences Inc from 2003 to 2025. This chart illustrates how STRATA Skin Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View STRATA Skin Sciences Inc share price for real-time trading data and today's change.
STRATA Skin Sciences Inc Cash Flow Conversion Ratio Explained
STRATA Skin Sciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
STRATA Skin Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STRATA Skin Sciences Inc ranked by their cash flow conversion efficiency. Also see SSKN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Malvern International
LSE:MLVN
|
-0.476x |
|
Europlasma SA
PA:ALEUP
|
0.657x |
|
PHILION SE O.N.
F:PH6
|
N/A |
|
XLMedia PLC
LSE:XLM
|
-0.008x |
|
Carisma Therapeutics Inc.
NASDAQ:CARM
|
-2.201x |
|
FAT Brands Inc
NASDAQ:FATBW
|
0.050x |
|
Chordate Medical Holding AB
ST:CMH
|
-0.514x |
|
Ukrproduct Group
LSE:UKR
|
0.227x |
Annual Cash Flow Conversion Efficiency for STRATA Skin Sciences Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of STRATA Skin Sciences Inc from 2003 to 2025. Review how much free cash does STRATA Skin Sciences Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.91 Million | $-2.79 Million | -0.961x | -2641.00% |
| 2024-12-31 | $4.97 Million | $188.00K | 0.038x | +192.44% |
| 2023-12-31 | $12.69 Million | $-519.00K | -0.041x | +19.41% |
| 2022-12-31 | $21.83 Million | $-1.11 Million | -0.051x | -185.53% |
| 2021-12-31 | $25.41 Million | $1.51 Million | 0.059x | -26.70% |
| 2020-12-31 | $25.89 Million | $2.10 Million | 0.081x | +4.06% |
| 2019-12-31 | $28.65 Million | $2.23 Million | 0.078x | -16.06% |
| 2018-12-31 | $31.25 Million | $2.90 Million | 0.093x | -50.20% |
| 2017-12-31 | $22.25 Million | $4.14 Million | 0.186x | +750.73% |
| 2016-12-31 | $14.72 Million | $322.00K | 0.022x | +105.34% |
| 2015-12-31 | $16.09 Million | $-6.58 Million | -0.409x | +71.62% |
| 2014-12-31 | $12.28 Million | $-17.71 Million | -1.443x | +38.35% |
| 2013-12-31 | $8.30 Million | $-19.41 Million | -2.340x | -70.12% |
| 2012-12-31 | $13.98 Million | $-19.22 Million | -1.376x | -134.86% |
| 2011-12-31 | $29.81 Million | $-17.46 Million | -0.586x | +1.04% |
| 2010-12-31 | $31.80 Million | $-18.82 Million | -0.592x | -3.70% |
| 2009-12-31 | $30.32 Million | $-17.30 Million | -0.571x | +46.85% |
| 2008-12-31 | $15.09 Million | $-16.20 Million | -1.074x | -101.89% |
| 2007-12-31 | $20.77 Million | $-11.05 Million | -0.532x | -11.79% |
| 2006-12-31 | $21.31 Million | $-10.14 Million | -0.476x | -48.05% |
| 2005-12-31 | $18.25 Million | $-5.87 Million | -0.321x | -137.23% |
| 2004-12-31 | $-3.55 Million | $-3.06 Million | 0.863x | -88.93% |
| 2003-12-31 | $-218.00K | $-1.70 Million | 7.798x | -- |
About STRATA Skin Sciences Inc
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer … Read more